RCS - BATM Advanced Comm - ADOR and BIOASTER to develop STI diagnostic tests

Batm Advanced CommunicationsAnnouncement

27/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221027:nRSa2518Ea&default-theme=true

RNS Number : 2518E  BATM Advanced Communications Ld  27 October 2022

LEI: 213800FLQUB9J289RU66

27 October 2022

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Collaboration with BIOASTER to develop molecular diagnostic tests

ADOR Diagnostics collaborates with BIOASTER to develop STI diagnostic tests

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for
networking solutions and medical laboratory systems, is pleased to announce
that the Group's associate company, ADOR Diagnostics ("ADOR"), has entered
into a cooperation agreement with BIOASTER, the French Microbiology Technology
Research Institute, to develop molecular diagnostic tests for sexually
transmitted infections ("STIs").

 

In line with its stated strategy, the Group is expanding the range of panels
in the ADOR system, NATlab™, for groups of diseases - the panel for
detecting STIs will join the panels for detecting meningitis, respiratory
diseases and, in development, tuberculosis (TB), which will broaden the base
of tests and increase the attractiveness of the solution in the various
markets. This will also significantly increase the addressable market for
NATlab, with the diagnosis of STIs having a global market value of c. $1bn.

 

The NATlab molecular diagnostics system is designed to provide rapid
sample-to-answer isothermal testing of pathogens, with different cartridges
for different infectious disease panels. Through the collaboration with
BIOASTER, BATM expects to be able to accelerate the development of an STI
panel by leveraging BIOASTER's significant experience in R&D of molecular
diagnostics. BIOASTER will also direct the clinical evaluation of the tests
using clinical specimens of high quality.

 

BIOASTER is a not-for-profit Technological Research Institute, headquartered
in Lyon, France, dedicated to applied microbiology, formed by the French
Government. BIOASTER conducts innovative collaborative research, with and for
public and private partners in the four major application fields of
microbiology in human and veterinary infectious diseases: vaccines,
antimicrobials, diagnosis and microbiota. BIOASTER has more than 100
employees, including 80 scientists and engineers originating from 16 different
countries, involved in collaborative projects.

 

Dr. Zvi Marom, Chief Executive Officer of BATM, said: "We are pleased to begin
this partnership with BIOASTER to expand ADOR's platform capabilities with
regards to the diagnosis of STIs. The incidence of STIs is widespread and
increasing globally and, if left undiagnosed and untreated, can lead to
infertility, chronic pain and even death. By working with BIOASTER, we expect
to accelerate the development of molecular diagnostic tests that can rapidly
and simply identify the infection-causing pathogen to enable the correct
treatment to be administered without delay."

 

Xavier Morge, Chief Executive Officer of BIOASTER, added: "We are excited to
start this partnership with ADOR Diagnostics to help expand the range of
clinical applications offered by the NATlab diagnostic platform in the field
of infectious diseases. This collaboration fits perfectly with our mission to
accelerate the innovation of our industrial partners and facilitate the
development of their products, to the benefit of the patients."

 

 

 

 

 

Enquiries:

 

 BATM Advanced Communications
 Dr. Zvi Marom, Chief Executive Officer  +972 9866 2525
 Moti Nagar, Chief Financial Officer

 Gracechurch Group
 Harry Chathli, Claire Norbury           +44 20 4582 3500

 

 

Forward-looking statements

 

This document contains forward-looking statements. Those statements reflect
the current opinions, evaluations and estimations of the Group's management,
and are based on the current data regarding the Group's business as is
detailed in this document and in the Group's periodical, interim and immediate
reports. The Group does not undertake any obligation or make any
representation that actual results and events will be in line with those
statements, and stresses that they may differ materially from those
statements, due to changes in the Group's business, market, competition,
demand for the Group's products or services, general economic factors or other
factors that can influence the Group's business and results, and due to
information and factors that are currently unknown to the Group's management
and that, if known, would affect the management's opinions, evaluations or
estimations. The Group will report the actual results and events according to
its legal, accounting and regulatory obligations, and does not undertake any
other obligation to report them or their deviations from the forward-looking
statements, or to update any of the forward-looking statements in this
document or to report that it is not valid anymore.

 

 

Further detail about BIOASTER

Created in 2012, following the French initiative of Technology Research
Institutes, BIOASTER is a not-for-profit foundation developing a unique
technological and innovative model to support the latest challenges in
microbiology. In particular, BIOASTER uses and develops high value
technological innovations that accelerate development of medical solutions for
populations and personalized medicine. The aim of BIOASTER is to bring
together academic, industry and its capacities and specific knowledge to
develop and execute high impact collaborative projects requiring industry
compatible innovative technologies.

 

Key figures:

• 4 fields of expertise: antimicrobials, diagnostics, microbiota, vaccines

• BSL2 & BSL3 laboratories in Lyon and Paris

• 100+ employees, including 80% of scientific experts, 17 nationalities

• 250+ research contracts, involving 93 private partners, 54 public
partners.

 

Press contact for BIOASTER: olivier.charzat@bioaster.org

www.bioaster.org

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZMZGRVGGZZM